These novel therapies , Semaglutide , represent a remarkable advancement in managing metabolic dysfunction and possibly associated conditions . These drugs are grouped as GLP-1 hormone stimulators, indicating they function to emulate the body's GLP-1 hormone , enhancing insulin secretion and lowe